Monday, October 13, 2025 10/13/2025

Bioreactor for Manufacturing Chemotactically Competent Immune Cell Therapies

Award Number: R61CA281785
ORGANIZATION: NATIONAL CANCER INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 05/01/2024
PERIOD OF PERFORMANCE END DATE: 04/30/2025

Group Awards By:

View Award Description

Bioreactor for Manufacturing Chemotactically Competent Immune Cell Therapies - PROJECT SUMMARY Current cell expansion procedures for antigen-specific CAR T cells and CAR NK cells result in cells with a broad repertoire of chemokine receptors. Upon infusion, they migrate to off-tumor healthy tissues and exert toxicities by targeting antigens expressed at basal levels. The ability to produce therapeutic cells with affinity to migrate into the tumor microenvironment (TME) is a critical unmet need. The investigating team’s mission is to harness the immune system to treat solid tumors. In line with this mission, the objectives of this R61 are to 1) develop a prototype of the bioreactor to selectively culture chemotactically competent cell-based therapies (CAR T, CAR NK-92), and 2) demonstrate use of this subset for migrating through a tissue-mimicking barrier and kill epithelial ovarian cancer cells in an antigen-specific manner. The rationale for this effort is that it will disrupt the status quo of current cell manufacturing technology, which generates therapeutic cells that traffic not only to tumors but also to healthy tissue. The team will conduct the R61 project under two milestone-driven aims: 1) Develop bioreactor for generating chemotactically competent CAR NK-92 cells; 2) Demonstrate utility of the bioreactor for generating chemotactically competent CAR T cells. In a follow-on R33, the team will use the bioreactor to scale up the production of these chemotactically competent cell therapies for preclinical mouse studies. The impact of bioreactor will be in making treatments safer (by mitigating off-tumor migration of therapeutic cells) and affordable (by reducing manual intervention in the closed-system bioreactor). Mitigating off-tumor migration will reduce the burden of manufacturing because most of the therapeutic cells will reach the target TME site. The significance of this project is also supported by its applicability to other immune cells (CAR NK cells, CAR macrophages) that are currently in development for targeting solid tumors.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2025 ( Subtotal = -$43,800 )
2025	2024	SRI INTERNATIONAL	333 RAVENSWOOD AVE	MENLO PARK	CA	94025	SAN MATEO	USA	Cancer Biology Research	002	1	7/25/2025	NEW	-$43,800
2025	2024	SRI INTERNATIONAL	333 RAVENSWOOD AVE	MENLO PARK	CA	94025	SAN MATEO	USA	Cancer Biology Research	001	1	4/10/2025	NEW	$0
2025	2024	SRI INTERNATIONAL	333 RAVENSWOOD AVE	MENLO PARK	CA	94025	SAN MATEO	USA	Cancer Biology Research	000	1	10/28/2024	NEW	$0
														Subtotal = -$43,800

Issue Date FY: 2024 ( Subtotal = $375,016 )
2024	2024	SRI INTERNATIONAL	333 RAVENSWOOD AVE	MENLO PARK	CA	94025	SAN MATEO	USA	Cancer Biology Research	000	1	5/1/2024	NEW	$375,016
														Subtotal = $375,016

Grand Total All Awards = $331,216

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Bioreactor for Manufacturing Chemotactically Competent Immune Cell Therapies

Award Number: R61CA281785

ORGANIZATION: NATIONAL CANCER INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 05/01/2024

PERIOD OF PERFORMANCE END DATE: 04/30/2025

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer